Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 449-457

  Yoshida, Minoru ^a   Tamura, Kazuo ^b   Imamura, Masahiro ^c   Niitsu, Yoshiro ^d   Sasaki, Takeshi ^e   Urabe, Akio ^f   Ohyashiki, Kazuma ^g   Naoe, Tomoki ^h   Kanamaru, Akihisa ⁱ   Tanimoto, Mitsune ^j   Masaoka, Tohru ^k  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e NTT East Tohoku Hospital   (Japan)

^f Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j OKAYAMA UNIVERSITY   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

more..

Author keywords

Echinocandin; Empirical therapy; Febrile neutropenia; Fungal infection; Hematological disorders; Micafungin

Indexed keywords

ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; GALACTOMANNAN; MICAFUNGIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD DISEASE; BRAIN HEMORRHAGE; BREAST CALCIFICATION; CHLORIDE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG THERAPY; DRUG WITHDRAWAL; EMPIRICAL ANTIFUNGAL THERAPY; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HYPOMOTILITY; HEART FAILURE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; JAPANESE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER FAILURE; LIVER FUNCTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; JAPAN; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857362648     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1316-y     Document Type: Article

References (36)

1. WT Hughes D Armstrong GP Bodey EJ Bow AE Brown, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 730 751 11850858 10.1086/339215 (Pubitemid 34194843)
2. JR Wingard 2004 Empirical antifungal therapy in treating febrile neutropenic patients Clin Infect Dis 39 S38 S43 15250019 10.1086/383052 1:CAS:528:DC%2BD2cXntVahs7o%3D (Pubitemid 38971474)
3. M Tomishima H Ohki A Yamada H Takasugi K Maki, et al. 1999 FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity J Antibiot (Tokyo) 52 674 676 1:CAS:528:DyaK1MXkvFagsbw%3D (Pubitemid 29378227)
4. K Hatano Y Morishita T Nakai F Ikeda 2002 Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus J Antibiot (Tokyo) 55 219 222 1:CAS:528:DC%2BD38XitVeitLw%3D (Pubitemid 34285463)
5. PH Chandrasekar JD Sobel 2006 Micafungin: a new echinocandin Clin Infect Dis 42 1171 1178 16575738 10.1086/501020 1:CAS:528:DC%2BD28XktVGqtr4%3D
6. S Tawara F Ikeda K Maki Y Morishita K Otomo, et al. 2000 In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Antimicrob Agents Chemother 44 57 62 10602723 10.1128/AAC.44.1.57-62.2000 1:CAS:528:DC%2BD3cXhtFCnsA%3D%3D (Pubitemid 30010672)
7. T Nakai J Uno K Otomo F Ikeda S Tawara, et al. 2002 In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds Chemotherapy 48 78 81 12011539 10.1159/000057666 1:CAS:528:DC%2BD38Xjs1GksLk%3D (Pubitemid 34507599)
8. F Ikeda Y Wakai S Matsumoto K Maki E Watabe, et al. 2000 Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis Antimicrob Agents Chemother 44 614 618 10681327 10.1128/AAC.44.3.614-618.2000 1:CAS:528:DC%2BD3cXhsVGhurk%3D (Pubitemid 30117950)
9. S Matsumoto Y Wakai T Nakai K Hatano T Ushitani, et al. 2000 Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis Antimicrob Agents Chemother 44 619 621 10681328 10.1128/AAC.44.3.619-621.2000 1:CAS:528:DC%2BD3cXhsVGhurY%3D (Pubitemid 30117951)
10. S Maesaki MA Hossain Y Miyazaki K Tomono T Tashiro, et al. 2000 Efficacy of FK463, a 1, 3-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice Antimicrob Agents Chemother 44 1728 1730 10817741 10.1128/AAC.44.6.1728-1730.2000 1:CAS:528: DC%2BD3cXjs1OlsLY%3D (Pubitemid 30340827)
11. F Ikeda S Tanaka H Ohki S Matsumoto K Maki, et al. 2007 Role of micafungin in the antifungal armamentarium Curr Med Chem 14 1263 1275 17504145 10.2174/092986707780597970 1:CAS:528:DC%2BD2sXltFejs74%3D (Pubitemid 46739326)
12. S Kohno T Masaoka H Yamaguchi T Mori A Urabe, et al. 2004 A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan Scand J Infect Dis 36 372 379 15287383 10.1080/ 00365540410020406 1:CAS:528:DC%2BD2cXjvVChur0%3D (Pubitemid 38967695)
13. NT de Wet AJ Bester JJ Viljoen F Filho JM Suleiman, et al. 2005 A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis Aliment Pharmacol Ther 21 899 907 15801925 10.1111/j.1365-2036.2005.02427.x (Pubitemid 40477250)
14. N de Wet A Llanos-Cuentas J Suleiman E Baraldi EF Krantz, et al. 2004 A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients Clin Infect Dis 39 842 849 15472817 10.1086/423377 (Pubitemid 39244300)
15. ER Kuse P Chetchotisakd CA da Cunha M Ruhnke C Barrios, et al. 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 1519 1527 17482982 10.1016/S0140-6736(07)60605-9 1:CAS:528:DC%2BD2sXkvFGmt7c%3D (Pubitemid 46670281)
16. PG Pappas CM Rotstein RF Betts M Nucci D Talwar, et al. 2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 883 893 17806055 10.1086/520980 1:CAS:528:DC%2BD2sXhtFOntr7I (Pubitemid 47580382)
17. TJ Walsh EJ Anaissie DW Denning R Herbrecht DP Kontoyiannis, et al. 2008 Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America Clin Infect Dis 46 327 360 18177225 10.1086/525258 1:CAS:528:DC%2BD1cXitlKqt7c%3D (Pubitemid 351265310)
18. H Fujita M Yoshida K Miura T Sano K Kito, et al. 2009 Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan adult leukemia study group Int J Hematol 90 191 198 19548066 10.1007/s12185-009-0367-5
19. T Ishikawa T Takata T Tomoyose M Masuda S Nakachi, et al. 2006 The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents Jpn J Chemother 54 125 128
20. M Yanada H Kiyoi M Murata M Suzuki M Iwai, et al. 2006 Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia Intern Med 45 259 264 16595990 10.2169/internalmedicine.45. 1498
21. T Toubai J Tanaka S Ota A Shigematsu Y Shono, et al. 2007 Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies Intern Med 46 3 9 17202726 10.2169/internalmedicine.46.6021 (Pubitemid 46062246)
22. K Tamura A Urabe M Yoshida A Kanamaru Y Kodera, et al. 2009 Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders Leuk Lymphoma 50 92 100 19172498 10.1080/10428190802635500 1:CAS:528:DC%2BD1MXhtVCrtrw%3D
23. DW Kubiak JM Bryar AM McDonnell JO Delgado-Flores E Mui, et al. 2010 Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis Clin Ther 32 637 648 20435233 10.1016/j.clinthera. 2010.04.005 1:CAS:528:DC%2BC3cXosVSnurY%3D
24. N Goto T Hara H Tsurumi K Ogawa J Kitagawa, et al. 2010 Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies Am J Hematol 85 872 876 20882524 10.1002/ajh.21858 1:CAS:528:DC%2BC3cXhsFWgsbzL
25. JS Park DH Kim CW Choi SH Jeong JH Choi, et al. 2010 Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases Acta Haematol 124 92 97 20664196 10.1159/000315558 1:CAS:528:DC%2BC3cXht1GnsrbE
26. S Ascioglu JH Rex B de Pauw JE Bennett J Bille, et al. 2002 Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 34 7 14 11731939 10.1086/323335 1:STN:280:DC%2BD3MnosVOltg%3D%3D (Pubitemid 33152659)
27. ICH Harmonised Tripartite Guideline, Current step 4 version, dated 27 October 1994: Clinical Safety Data Management: definitions and Standards for Expedited Reporting E2A. http://www.ich.org/LOB/media/MEDIA436.pdf. Accessed: October 1994
28. J Maertens K Theunissen G Verhoef, et al. 2005 Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41 1242 1250 16206097 10.1086/496927 1:CAS:528:DC%2BD2MXht1WisbfE (Pubitemid 41534660)
29. C Cordonnier C Pautas S Maury, et al. 2009 Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial Clin Infect Dis 48 1042 1051 19281327 10.1086/597395 1:CAS:528:DC%2BD1MXltFektL4%3D
30. TJ Walsh RW Finberg C Arndt J Hiemenz C Schwartz National Institute of Allergy and Infectious Diseases Mycoses Study Group 1999 Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia N Engl J Med 340 764 771 10072411 10.1056/NEJM199903113401004 1:CAS:528: DyaK1MXhvFOqu7k%3D (Pubitemid 29114295)
31. M Boogaerts DJ Winston EJ Bow G Garber AC Reboli AP Schwarer, et al. 2001 Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy Ann Intern Med 135 412 422 11560454 1:CAS:528:DC%2BD3MXntFGgtrg%3D (Pubitemid 32845866)
32. TJ Walsh P Pappas DJ Winston HM Lazarus F Petersen J Raffalli, et al. 2002 National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 225 234 11807146 10.1056/NEJM200201243460403 1:CAS:528:DC%2BD38XmslGgsg%3D%3D (Pubitemid 34438861)
33. TJ Walsh H Teppler GR Donowitz JA Maertens LR Baden, et al. 2004 Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 1391 1402 15459300 10.1056/NEJMoa040446 1:CAS:528:DC%2BD2cXotVOrsro%3D (Pubitemid 39288165)
34. T Obayashi M Yoshida T Mori H Goto A Yasuoka, et al. 1995 Plasma 1,3-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes Lancet 345 17 20 7799700 10.1016/S0140-6736(95)91152-9 1:STN:280:DyaK2M%2FpslKrsw%3D%3D
35. B de Pauw TJ Walsh JP Donnelly DA Stevens JE Edwards, et al. 2008 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813 1821 18462102 10.1086/588660
36. M Yoshida 2006 Usefulness of determination of β-D-glucan in the diagnosis of deep mycosis-experience in Japan Med Mycol 44 Sup 1 S185 S189 10.1080/13693780600897997 1:CAS:528:DC%2BD2sXktVSnsg%3D%3D (Pubitemid 44524103)